UroSuite from Myriad Genetics (MYGN) to enhance tailored treatment
Myriad Genetics, Inc. (Quick quote MYGNMYGN – Free Report) recently announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests covering all stages of prostate cancer care. The UroSuite includes the company’s Prolaris prostate cancer test, MyRisk hereditary cancer test, BRACAnalysis CDx, and accurate tumor molecular profiling test. The latest launch is …
UroSuite from Myriad Genetics (MYGN) to enhance tailored treatment Read More »